Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemias

Authors: Kota, Vamsi ^*, Brümmendorf, Tim H., Gambacorti-Passerini, Carlo, Lipton, Jeff H., Kim, Dong-Wook, An, Fiona, Leip, Eric, Crescenzo, Rocco J., Ferdinand, Roxanne, Cortes, Jorge E.

Source: In Leukemia Research December 2021 111

Progression-free survival by local investigator versus independent central review: Comparative analysis of the AGO-OVAR16 Trial

Authors: Floquet, Anne, Vergote, Ignace, Colombo, Nicoletta, Fiane, Bent, Monk, Bradley J., Reinthaller, Alexander, Calvert, Paula, Herzog, Thomas J., Meier, Werner, Kim, Jae-Weon, del Campo, Josep M., Friedlander, Michael, Pisano, Carmela, Isonishi, Seiji, Crescenzo, Rocco J., Barrett, Catherine, Wang, Karrie, Mitrica, Ionel, du Bois, Andreas

Source: In Gynecologic Oncology January 2015 136(1):37-42

Genomic Landscape of Ibrutinib- and/or Acalabrutinib-intolerant Patients with B-cell Malignancies Treated with Zanubrutinib in a Phase 2 Study

Authors: Xu, Linlin, Shadman, Mazyar, Flinn, Ian W., Levy, Moshe, Porter, Ryan, Burke, John M., Zafar, Syed F., Cultrera, Jennifer L., Misleh, Jamal, Kingsley, Edwin C., Yimer, Habte A., Freeman, Benjamin B., Chaudhry, Arvind, Tumula, Praveen K., Gandhi, Mitul, Crescenzo, Rocco J., By, Kunthel, Cohen, Aileen Cleary, Idoine, Adam, Manda, Sudhir, Sharman, Jeff P.

Source: In Blood 2 November 2023 142 Supplement 1:6510-6510

Sonrotoclax (BGB-11417) in Combination with Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma with t(11;14): Safety, Efficacy, and Determination of Recommended Phase 2 Dose

Authors: Quach, Hang, Sborov, Doug, Kazandjian, Dickran, Spencer, Andrew, Low, Michael, Bal, Susan, Callander, Natalie S., Cheng, Huan, Patel, Sheel, Crescenzo, Rocco J., Agarwal, Amit, Dhakal, Binod

Source: In Blood 2 November 2023 142 Supplement 1:1011-1011

Zanubrutinib in Acalabrutinib-Intolerant Patients (Pts) with B-Cell Malignancies

Authors: Shadman, Mazyar, Flinn, Ian W., Kingsley, Edwin C., Freeman, Benjamin B., Levy, Moshe, Farber, Charles M., D'Olimpio, James, Cultrera, Jennifer L., Zhang, Ben, Crescenzo, Rocco J., Idoine, Adam, Zhang, Xiaoping, By, Kunthel, Sharman, Jeff P.

Source: In Blood 2 November 2023 142 Supplement 1:3279-3279

Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia.

Authors: Cortes, Jorge E., Muresan, Bogdan, Mamolo, Carla, Cappelleri, Joseph C., Crescenzo, Rocco J., Su, Yun, Gambacorti-Passerini, Carlo, Heeg, Bart, Douglas Smith, B.

Source: Current Medical Research & Opinion; Sep2019, Vol. 35 Issue 9, p1615-1622, 8p

Subject Terms: DASATINIB, CHRONIC myeloid leukemia, PROTEIN-tyrosine kinases, PROGRESSION-free survival

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

Impact of Diarrhea on Health-Related Quality of Life: Analysis of the Phase 3 BFORE Trial of Bosutinib Vs Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Authors: Brümmendorf, Tim H, Mamolo, Carla M. ^*, Reisman, Arlene ^*, Bushmakin, Andrew G ^*, Cappelleri, Joseph C ^*, Crescenzo, Rocco J. ^*, DeAnnuntis, Liza ^*, Viquiera, Andrea ^*, Cortes, Jorge E.

Source: In Blood 29 November 2018 132 Supplement 1:4264-4264

An Indirect Comparison between Bosutinib, Nilotinib and Dasatinib in First-Line Chronic Phase Chronic Myeloid Leukemia

Authors: Muresan, Bogdan ^*, Mamolo, Carla M. ^*, Cappelleri, Joseph C ^*, Crescenzo, Rocco J., Leip, Eric ^*, Viqueira, Andrea ^*, Heeg, Bart ^*

Source: In Blood 29 November 2018 132 Supplement 1:1742-1742

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: 12-Month Patient-Reported Outcomes from the BFORE Trial

Authors: Cortes, Jorge E., Gambacorti-Passerini, Carlo, Deininger, Michael W., Mauro, Michael J., Chuah, Charles, Kim, Dong-Wook, Dyagil, Iryna ^*, Glushko, Nataliia ^*, Milojkovic, Dragana ^*, le Coutre, Philipp D., García Gutiérrez, Valentín, Reilly, Laurence ^*, Jeynes-Ellis, Allison ^*, Crescenzo, Rocco J. ^*, Mamolo, Carla ^*, Reisman, Arlene ^*, Bardy-Bouxin, Nathalie ^*, Hochhaus, Andrea, Brümmendorf, Timothy H.

Source: In Blood 8 December 2017 130 Supplement 1:2895-2895

Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia in the BFORE Trial: Results By 3-Month BCR-ABL1 Transcript Level

Authors: Hochhaus, Andreas, Gambacorti-Passerini, Carlo, Deininger, Michael W., Mauro, Michael J., Chuah, Charles, Kim, Dong-Wook, Dyagil, Iryna ^*, Glushko, Nataliia ^*, Milojkovic, Dragana ^*, le Coutre, Philipp D., García Gutiérrez, Valentín, Reilly, Laurence ^*, Jeynes-Ellis, Allison ^*, Crescenzo, Rocco J. ^*, Leip, Eric ^*, Bardy-Bouxin, Nathalie ^*, Brümmendorf, Timothy H., Cortes, Jorge E.

Source: In Blood 8 December 2017 130 Supplement 1:1618-1618

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.